Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:35:03 13/09/2024 BST			5-day change	1st Jan Change
168.20 ^EUR	-0.21%		-0.36%	+16.72%

09-13	MERCK KGAA : UBS keeps its Buy rating	ZD
09-09	German Shares Cheer Likelihood of September ECB Rate Cut	MT

Merck KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024

August 01, 2024 at 03:06 am

Merck KGaA reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was EUR 5,352 million compared to EUR 5,302 million a year ago. Net income was EUR 607 million compared to EUR 704 million a year ago. Basic earnings per share from continuing operations was EUR 1.4 compared to EUR 1.62 a year ago. Diluted earnings per share from continuing operations was EUR 1.4 compared to EUR 1.62 a year ago.
For the six months, sales was EUR 10,472 million compared to EUR 10,595 million a year ago. Net income was EUR 1,302 million compared to EUR 1,500 million a year ago. Basic earnings per share from continuing operations was EUR 2.99 compared to EUR 3.45 a year ago. Diluted earnings per share from continuing operations was EUR 2.99 compared to EUR 3.45 a year ago.

Latest news about Merck KGaA

MERCK KGAA : UBS keeps its Buy rating	09-13	ZD
German Shares Cheer Likelihood of September ECB Rate Cut	09-09	MT
Merck Gets EU Approval for Keytruda Cancer Therapy	09-03	DJ
Merck KGaA Doses First Patient in Late-stage Myasthenia Gravis Study	08-29	MT
Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis	08-29	CI
Chemical and pharmaceutical industry: research spending to remain virtually stable	08-29	DP
Merck KGaA Plans EUR800 Million Issuance of Subordinated Hybrid Instruments	08-20	MT
JPMorgan rates Merck KGaA at 'Overweight' - Target 190 euros	08-09	DP
MERCK KGAA : JP Morgan maintains a Buy rating	08-09	ZD
Bernstein: Sanofi Set to Record Growth on Expected Multiple Sclerosis Boost	08-08	MT
Biotech firm Recursion to buy smaller peer Exscientia for $688 million	08-08	RE
MERCK KGAA : UBS raises price target	08-07	CF
MERCK KGAA : Receives a Buy rating from UBS	08-06	ZD
MERCK KGAA : Gets a Buy rating from Deutsche Bank	08-06	ZD
MERCK KGAA : DZ Bank reaffirms its Buy rating	08-05	ZD
MERCK : All lights are green for a robust H2	08-02
Global markets live: Shell, Chevron, Boeing, Walt Disney, Qualcomm...	08-01
Germany's Merck KGaA Wraps Up Acquisition of US-based Mirus Bio	08-01	MT
Merck KGaA increases sales - Semiconductors and Pharmaceuticals provide support	08-01	DP
Transcript : Merck KGaA, Q2 2024 Earnings Call, Aug 01, 2024	08-01
MERCK KGAA : Jefferies gives a Buy rating	08-01	ZD
MERCK KGAA : UBS reiterates its Buy rating	08-01	ZD
MERCK KGAA : Gets a Buy rating from Barclays	08-01	ZD
MERCK KGAA : Deutsche Bank remains its Buy rating	08-01	ZD
MERCK KGAA : JP Morgan reiterates its Buy rating	08-01	ZD

Chart Merck KGaA

Duration

Period

More charts

Company Profile

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).

Employees

62,176

Sector

Pharmaceuticals

Calendar

16/10/2024 - Capital Markets Day

More about the company